| Literature DB >> 32525610 |
Marie-Luise Bouvier1, Karin Fehsel1, Andrea Schmitt2,3, Eva Meisenzahl-Lechner1, Wolfgang Gaebel1, Martina von Wilmsdorff1.
Abstract
OBJECTIVE: Sex-dependent disturbances of peripheral glucose metabolism are known complications of antipsychotic drug treatment. The influence of long-term clozapine and haloperidol medication on hypothalamus, maintaining aspects of internal body homeostasis, has not yet been completely clarified.Entities:
Keywords: clozapine; dopamine receptors; glucose transporters; haloperidol; sex differences
Mesh:
Substances:
Year: 2020 PMID: 32525610 PMCID: PMC7428470 DOI: 10.1002/brb3.1694
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Mean and standard error of hypothalamic total protein, albumin, malondialdehyde, total glucose, glycogen, lactate, pyruvate levels, and lactate/pyruvate ratio of male and female Sprague Dawley rats
| Male control | Male halo | Male cloz | Female control | Female halo | Female cloz | |
|---|---|---|---|---|---|---|
| Protein level membrane | ||||||
| Hypothalamus (mg/ml) | 9.08 ± 0.23 | 8.67 ± 0.14 | 8.74 ± 0.34 | 9.10 ± 0.31 | 8.86 ± 0.22 | 8.89 ± 0.33 |
| Protein level cytosol | ||||||
| Hypothalamus (mg/ml) | 9.17 ± 0.40 | 10.00 ± 0.35 | 9.11 ± 0.40 | 8.76 ± 0.33 | 8.49 ± 0.44 | 9.20 ± 0.46 |
| Albumin | ||||||
| Hypothalamus (mg/ml) | 9.14 ± 0.81 | 8.99 ± 0.59 | 7.3 ± 0.53 | 7.22 ± 0.60 | 7.39 ± 0.51 | 8.00 ± 0.54 |
| Oxidative stress | ||||||
| Hypothalamus (MDAµmol/ml) | 0.037 ± 0.007 | 0.029 ± 0.006 | 0.025 ± 0.006 | 0.034 ± 0.01 | 0.032 ± 0.01 | 0.034 ± 0.007 |
| Fasting glucose | ||||||
| Serum (µg/ml) | 47.46 ± 5.44 | 64.05 ± 4.58 | 57.22 ± 3.81 | 34.37 ± 1.59 | 40.33 ± 5.45 | 45.42 ± 2.99 |
| Total glucose | ||||||
| Hypothalamus (µg/ml) | 8.70 ± 2.1 | 13.59 ± 3.2 | 7.89 ± 1.5 | 7.02 ± 1.2 | 8.85 ± 1.5 | 9.41 ± 1.9 |
| Glycogen | ||||||
| Hypothalamus (µg/ml) | 4.87 ± 0.52 | 4.38 ± 0.53 | 3.98 ± 0.75 | 5.24 ± 0.59 | 5.16 ± 0.91 | 5.41 ± 0.64 |
| Lactate | ||||||
| Hypothalamus (mmol/L) | 2.06 ± 0.072 | 2.14 ± 0.076 | 2.25 ± 0.085 | 2.05 ± 0.059 | 2.21 ± 0.072 | 2.31 ± 0.095 |
| Pyruvate | ||||||
| Hypothalamus (µmol/L) | 64.64 ± 11.5 | 58.14 ± 7.1 | 47.71 ± 10.3 | 50.07 ± 12.02 | 41.93 ± 5.0 | 63.64 ± 13.8 |
| Lactate/pyruvate ratio | ||||||
| Hypothalamus | 40.95 ± 6.2 | 41.42 ± 4.8 | 70.04 ± 14.7 | 68.67 ± 16.9 | 59.23 ± 6.5 | 58.33 ± 17.3 |
cloz, clozapine medicated; halo, haloperidol medicated; with n group = 10.
p < .05 and **p < .001 as significant.
FIGURE 1Expression of the dopamine 2 (D2R) and dopamine 4 (D4R) receptor in hypothalamic membrane fraction after 12‐week medication of clozapine or haloperidol in male and female Sprague Dawley rats (Cloz, clozapine medicated; Cont, control; f, female; Halo, haloperidol medicated; KD, Kilo Dalton; m, male). n group = 10 with *p ≤ .05 and **p < .001. The autoradiographs show the dopamine receptor expression of pooled values of each treatment group
FIGURE 2Expression of the glucose transporters Glut1 and Glut3 in hypothalamic membrane fraction after 12‐week medication of clozapine or haloperidol in male and female Sprague Dawley rats (Cloz, clozapine medicated; Cont, control; f, female; Halo, haloperidol medicated; m, male), n group = 10 for Glut1 and n group = 5 for Glut3 with *p ≤ .05, **p < .001 and ***p < .0001. The autoradiographs show the glucose transporter expression of pooled probes of each treatment group
FIGURE 3Expression of the melanocortin 4 receptor (MC4R) in hypothalamic membrane fraction after 12‐week medication of clozapine or haloperidol in male and female Sprague Dawley rats (Cloz, clozapine medicated; Cont, control; f, female; Halo, haloperidol medicated; m, male). n group = 10